Gamma-delta T-cell phenotype is associated with significantly decreased survival in cutaneous T-cell lymphoma

Blood ◽  
2003 ◽  
Vol 101 (9) ◽  
pp. 3407-3412 ◽  
Author(s):  
Jorge R. Toro ◽  
David J. Liewehr ◽  
Nina Pabby ◽  
Lynn Sorbara ◽  
Mark Raffeld ◽  
...  
Keyword(s):  
T Cell ◽  
Cell Lymphoma ◽  
T Cell Lymphoma ◽  
Cell Phenotype ◽  
Cutaneous T Cell Lymphoma ◽  
Γδ T Cell ◽  
Cellular Expression ◽  
T Cell Lymphomas ◽  
Cutaneous Lymphomas ◽  
Significant Difference

The importance of αβ versus γδ T-cell subset antigen expression in the classification of peripheral T-cell lymphomas is still unclear. The objective of this study was to investigate the prognostic value of T-cell receptor–δ1 (TCRδ1) expression in primary cutaneous T-cell lymphomas. TCRδ1 cellular expression was assessed in skin biopsy specimens of 104 individuals with cutaneous T-cell lymphoma by immunohistochemistry. Both univariate (Kaplan-Meier) and multivariate (Cox regression) analyses were conducted to determine which variables (T-cell subtype, hemophagocytosis, histologic profile, age, sex, and adenopathy) were significantly associated with survival. Univariate analysis indicated that there was a statistically significant difference in survival between the patients with αβ cutaneous T-cell lymphoma and patients with γδ cutaneous T-cell lymphoma (P < .0001). There was also a statistically significant decrease in survival among patients who had subcutaneous involvement compared with patients who had epidermotropic and/or dermal involvement (P < .0001). Cox model analysis indicated that TCRδ1 expression was the factor that was most closely associated with decreased survival (P < .0001). Among those patients with cutaneous γδ T-cell lymphoma (n = 33), there was a trend for decreased survival for patients who had histologic evidence of subcutaneous fat involvement in comparison with patients who had epidermotropic or dermal patterns of infiltration (P = .067). No other prognostic factors were identified as having a notable association with outcome in this subgroup. TCRδ1 expression in primary cutaneous lymphomas is an independent prognostic factor associated with decreased survival.

A case of cutaneous T-cell lymphoma expressing γδ T-cell receptors

1993 ◽  
Vol 28 (2) ◽  
pp. 355-360 ◽  
Author(s):  
Mayumi Fujita ◽  
Yoshiki Miyachi ◽  
Fukumi Furukawa ◽  
Eiko Toichi ◽  
Ikuko Furukawa ◽  
...  
Keyword(s):  
T Cell ◽  
T Cell Receptors ◽  
Cell Lymphoma ◽  
T Cell Lymphoma ◽  
Cutaneous T Cell Lymphoma ◽  
Γδ T Cell ◽  
Cell Receptors

Expression of Coxsackie Adenovirus Receptor in Cutaneous T-Cell Lymphoma: Potential for Skin Targeted Gene Therapy.

Blood ◽  
2006 ◽  
Vol 108 (11) ◽  
pp. 4651-4651
Author(s):  
Johnathan Ledet ◽  
Joshua May ◽  
Seth Billelo ◽  
Ellen Friday ◽  
Mary Nordberg ◽  
...  
Keyword(s):  
Gene Therapy ◽  
T Cell ◽  
Cell Lymphoma ◽  
Normal Skin ◽  
T Cell Lymphoma ◽  
Molecular Therapy ◽  
Cutaneous T Cell Lymphoma ◽  
Coxsackie Adenovirus Receptor ◽  
Cutaneous Lymphomas ◽  
Adenovirus Receptor

Abstract Cutaneous T-cell lymphoma (CTCL) represents a spectrum of diseases characterized by the accumulation of clonal lymphocytes in the skin. It has been well established that primary cutaneous lymphomas of T-cell lineage have shown ALK protein expression. Furthermore, we have previously shown that ALK-ALCL cell lines highly express the coxsackie-adenovirus receptor (CAR), primary receptor for recombinant wild type-fiber adenovirus-derived vectors for gene therapy. Since skin-directed therapies are the preferred first-line treatment the presence of CAR in CTCL may be helpful in developing therapeutic modalities such gene or targeted molecular therapy. By using ALK-immunostaining, we analyzed retrospectively a series of human tissue primarily diagnosed as CTCL [5 mycosis fungoides (MF), 4 (ALCL)] or peripheral T cell lymphoma (1 PTCL) in order to establish the level of CAR expression in primary CTCL tissue. Fluorescence in situ hybridization (FISH) analyses were also performed on these cases using a locus specific DNA probe for the ALK/p2 locus. We used ALK identification because at the time when the primary diagnosis was placed, the samples were not tested for ALK expression. Patients ranged in age from 32–73 years old with a median age of 58. Normal skin biopsies from 8 patients were used as controls. The results of our analysis are illustrated in Table 1. TABLE 1. DIAGNOSIS SPECIMEN CAR INTENSITY/% ALK INTENSITY/% FISH CD30 ALCL RT ANKLE MASS 0 / 0 N/A N/A POS ALCL RT FLANK MASS 1+/ 80 1+ / 80 32% B-ANEUPLOID ALCL SKIN, LOWER RIGHT EXTREMITY 0 / 0 2+/ 10 NL POS PTCL SKIN, RT ARM 3+ / 95 3 +/ 70 MF SKIN, RT AXILLA 1 + / 5 3+ / 5 ALK POS MF SKIN 1+ / 5 3+ / 5 NL 21% ANEUPLOID MF SKIN, ARM 0 / 0 3+ / 90 NL (18% ANEUPLOID) POS (RARE) MF SKIN, LEFT BACK 2+ / 40 3+ / 95 NL MF SKIN, RT FOREARM 2+ / 30 1 + / 30 In this study, we show that the immunostaining of CAR in combination with classic ALK-immuno or ALK-FISH is feasible and helps in identifying CTCL cases candidate for skin targeted adenoviral-mediated gene therapy.

The use of single-fraction radiation therapy in cutaneous T-cell lymphoma

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. e19505-e19505
Author(s):  
A. M. Babbo ◽  
M. Chokshi ◽  
A. Rademaker ◽  
B. Mittal
Keyword(s):  
Radiation Therapy ◽  
T Cell ◽  
Cell Lymphoma ◽  
The United States ◽  
T Cell Lymphoma ◽  
Response To Treatment ◽  
Cutaneous T Cell Lymphoma ◽  
Single Fraction ◽  
Cutaneous Lymphomas

e19505 Background: Primary cutaneous lymphomas occur in 0.5 to 1 per 100,000 people every year in developed countries. Less than 1,000 cases of Mycosis Fungoides are diagnosed each year in the United States, with approximately 3 cases per 1,000,000 per year. Cutaneous T-cell lymphomas are responsive to radiation therapy, and local radiation therapy, total skin electron beam therapy, phototherapy (with UVB or PUVA), chemotherapy agents (nitrogen mustards, BCNU), retinoids, and steroids have all been used with varying degrees of success. Methods: This is a retrospective review of all cases of histology-proven cutaneous T-cell lymphoma treated with single-fraction radiation therapy at Northwestern Memorial Hospital in the Department of Radiation Oncology since 1990. We looked at response to treatment and local control. We reviewed the charts of 67 patients with cutaneous T-cell lymphoma, of which 40 patients and a total of 130 sites of disease received single-fraction radiation therapy and had available follow-up data. Results: Of the 130 lesions receiving a single-fraction of radiation, 86 (66%) received 800cGy in 1 fraction and 38 (29%) received 700cGy. 4 patients (3%) received 750cGy, 1 (<1%) received 550cGy and 1 (<1%) received 500cGy. Patients were treated with electron energies ranging from 6–18 MeV or photon energies ranging from 4–10 MV. Out of 130 lesions, 119 (92%) achieved a complete response (CR) to single-fraction radiation and 11 (8%) achieved a partial response (PR). There were 2 sites of relapse out of 130 treated sites, involving 2 patients. The median follow-up time was 4 months, mean follow-up time was 14 months, and 44% of patients had greater than 6 months of follow-up. Conclusions: This review of the experience at our institution since 1990 shows single-fraction radiation therapy to be an effective treatment for cutaneous T-cell lymphoma, with high response rates and very low relapse rates. No significant financial relationships to disclose.

Juvenile granulomatous cutaneous T cell lymphoma: a new entity in cutaneous lymphomas?

1997 ◽  
Vol 19 (5) ◽  
pp. 497 ◽  
Author(s):  
W. Kempf ◽  
R. Dummer ◽  
A. Häffner ◽  
B. Müller ◽  
C. Dommann-Scherrer ◽  
...  
Keyword(s):  
T Cell ◽  
Cell Lymphoma ◽  
T Cell Lymphoma ◽  
Cutaneous T Cell Lymphoma ◽  
Cutaneous Lymphomas

scholarly journals Detection of the human T cell lymphoma virus p19 in cells of some patients with cutaneous T cell lymphoma and leukemia using a monoclonal antibody.

1981 ◽  
Vol 154 (6) ◽  
pp. 1957-1964 ◽  
Author(s):  
M Robert-Guroff ◽  
F W Ruscetti ◽  
L E Posner ◽  
B J Poiesz ◽  
R C Gallo
Keyword(s):  
Monoclonal Antibody ◽  
T Cells ◽  
T Cell ◽  
Cell Lymphoma ◽  
T Cell Lymphoma ◽  
Cutaneous T Cell Lymphoma ◽  
Natural Reservoir ◽  
T Cell Lymphomas ◽  
Human T Cell ◽  
Type C

A monoclonal antibody specific for the internal p19 protein of a type-C retrovirus (HTLV) isolated from human neoplastic T cells has been developed. Its specificity has been shown by radioimmune precipitation and by affinity chromatography of iodinated HTLV proteins. By indirect immune fluorescence this antibody recognizes only HTLV-producing cells. Examination of cells from patients with cutaneous T cell lymphomas and leukemias and with other types of lymphomas and leukemias indicated that HTLV p19 expression is rare. The monoclonal antibody will be useful in determining the natural reservoir of HTLV, possibly in a subset of mature T cell neoplasias.

Primary cutaneous lymphomas in Peru

2006 ◽  
Vol 24 (18_suppl) ◽  
pp. 17566-17566
Author(s):  
B. Beltran ◽  
A. Carrasco ◽  
L. Vera ◽  
E. Salinas ◽  
M. Ticona ◽  
...  
Keyword(s):  
T Cell ◽  
B Cell ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
T Cell Lymphoma ◽  
Malignant Lymphomas ◽  
Large B Cell Lymphoma ◽  
T Cell Lymphomas ◽  
Cutaneous Lymphomas ◽  
Large B Cell

17566 Background: The clinicopathologic characteristics of malignant lymphomas vary according to geography. The aim of this study was to determine the relative frequency of cutaneous lymphomas and to examine the clinical relevance of the new WHO/EORTC classification in Peruvian cases of cutaneous lymphoma. Methods: We conducted a clinicopathologic retrospective study of a collection of 68 primary cutaneous lymphomas, diagnosed from 1997 to 2004 in a National General Hospital. The clinical records, haematoxylin & eosin-stained slides and immunohistochemical stains from 67 patients with malignant lymphomas of the skin were reviewed. HTLV-1 serology was made using ELISA and Western Blot methods. The statistical method was descriptive and survival was calculated using the Kaplan-Meier method. Results: Mean age at presentation was 62 years and the female/male ratio 1.5:1. T cell lymphomas were 88.6% and 11.4% were B-cell lymphomas. The most frequent cutaneous lymphoma was mycosis fungoides (MF) 30/67 (44.7%), Adult T-cell leukemia/lymphoma (ATLL) 13/67 (19.4%), unspecified peripheral T-cell lymphoma 4/67 (6%), lymphomatoid papulosis 2/67 (3%), leg-type diffuse large B-cell lymphoma 2/67 (3%), diffuse large B-cell lymphoma 2/67 (3%), subcutaneous panniculitis-like T-cell lymphoma 2/67 (3%), anaplastic large cell lymphoma 1/67 (1.4%), Sézary síndrome 1/67 (1.4%), nasal type extranodal NK/T-cell lymphoma 1/67 (1.4%), marginal zone B-cell lymphoma 1/67 (1.4%), follicle center lymphoma 1/67 (1.4%), intravascular lymphoma 1/67 (1.4%) and unclassifiable 5/67 ( 7.4%). Clinical stages of MF were: 60% stage I; 30% stage II; 3% stage III and 7% stage IV. 5-year survival was 77%. In ATLL group, 3 had smouldering type and 10 had cutaneous type. 5-year survival was 18%. Conclusions: In this retrospective analysis, cutaneous T cell lymphomas were prevalent; both MF and ATLL had the most frequency among primary cutaneous lymphomas in our hospital. ATLL had a poor 5-year survival. No significant financial relationships to disclose.

scholarly journals A Role for Regulatory T Cells in Cutaneous T-Cell Lymphoma; Induction of a CD4+CD25+Foxp3+ T-Cell Phenotype Associated with HTLV-1 Infection

2006 ◽  
Vol 126 (3) ◽  
pp. 690-692 ◽  
Author(s):  
Patrick T. Walsh ◽  
Bernice M. Benoit ◽  
Maria Wysocka ◽  
Nicole M. Dalton ◽  
Laurence A. Turka ◽  
...  
Keyword(s):  
T Cells ◽  
T Cell ◽  
Regulatory T Cells ◽  
Cell Lymphoma ◽  
T Cell Lymphoma ◽  
Cell Phenotype ◽  
Cutaneous T Cell Lymphoma

scholarly journals 2-Chlorodeoxyadenosine: an active agent in the treatment of cutaneous T- cell lymphoma

Blood ◽  
1992 ◽  
Vol 80 (3) ◽  
pp. 587-592 ◽  
Author(s):  
A Saven ◽  
CJ Carrera ◽  
DA Carson ◽  
E Beutler ◽  
LD Piro
Keyword(s):  
T Cell ◽  
Cell Lymphoma ◽  
Single Agent ◽  
Active Agent ◽  
T Cell Lymphoma ◽  
Treatment Modalities ◽  
Cutaneous T Cell Lymphoma ◽  
T Cell Lymphomas ◽  
Duration Of Response ◽  
Combination Regimens

Abstract Cutaneous T-cell lymphomas are disfiguring malignant lymphoproliferative disorders for which standard therapy has been principally palliative. 2-Chlorodeoxyadenosine (2-CdA), a new purine analogue resistant to degradation by adenosine deaminase that has substantial activity against lymphoid neoplasms, was administered to 16 patients with cutaneous involvement by T-cell lymphoma. All patients had failed topical treatment modalities and/or systemic therapies. Fifteen patients were evaluable; one patient was not evaluable due to incomplete therapy and follow-up. The overall response rate was 47%. Three of 15 patients (20%) achieved complete responses and four of 15 patients (27%) achieved partial responses. The median duration of response was 5 months. One patient remains in unmaintained complete remission at 52+ months. Therapy was well tolerated. Myelosuppression was the principal toxicity encountered, occurring in 8 of 15 (53%) patients. 2-CdA is an effective new agent for the treatment of cutaneous T-cell lymphoma and warrants further study both as a single agent and in combination regimens.

Sign in / Sign up

Export Citation Format

Share Document